{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:32:49Z","timestamp":1792683169504,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022876","name":"Photocure Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014841","name":"medac GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2026.01.029","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T19:57:49Z","timestamp":1771703869000},"page":"500-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group"],"prefix":"10.1016","volume":"89","author":[{"given":"Shilpa","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishoy M.","family":"Faltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyati","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Oualla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal S.","family":"Pohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdana","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.029_b0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bju.15856","article-title":"The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer","volume":"131","author":"Walraven","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.01.029_b0010","first-page":"11526","article-title":"Enhancing bladder cancer care through the multidisciplinary clinic approach","volume":"30","author":"Mark","year":"2023","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0015","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","article-title":"Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2023.05.005","article-title":"Definition and diagnosis of oligometastatic bladder cancer: a Delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty","volume":"84","author":"Bamias","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0030","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.1999.17.8.2546","article-title":"Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma","volume":"17","author":"Dodd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1464-410X.2011.10664.x","article-title":"Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic","volume":"110","author":"Blick","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.01.029_b0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.urolonc.2009.12.020","article-title":"Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy","volume":"30","author":"Ploeg","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0045","doi-asserted-by":"crossref","first-page":"195.e27","DOI":"10.1016\/j.urolonc.2022.01.002","article-title":"Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: a multicenter cohort from the European Association of Urology-Young Academic Urologists","volume":"40","author":"Lonati","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","article-title":"Staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer","volume":"5","author":"Voskuilen","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232141","article-title":"Optimization of time frame binning for FDOPA uptake quantification in glioma","volume":"15","author":"Girard","year":"2020","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2026.01.029_b0060","doi-asserted-by":"crossref","first-page":"S1200","DOI":"10.1016\/j.annonc.2023.09.1010","article-title":"2361MO Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC)","volume":"34","author":"Sridhar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0070","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bju.15188","volume":"126","author":"Del Giudice","year":"2020","journal-title":"BJU Int"},{"issue":"42","key":"10.1016\/j.eururo.2026.01.029_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/DEHT5407","article-title":"Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT","volume":"28","author":"James","year":"2024","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eururo.2026.01.029_b0080","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1464-410X.2007.06766.x","article-title":"Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour","volume":"99","author":"Cowan","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.01.029_b0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.urology.2014.03.040","article-title":"The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer","volume":"84","author":"Reese","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.01.029_b0090","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/JU.0000000000001602","article-title":"Cystoscopy and systematic bladder tissue sampling in predicting pT0 bladder cancer: a prospective trial","volume":"205","author":"Zibelman","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102087","article-title":"Honing the hunt: a comprehensive review of cell-free tumor DNA to predict neoadjuvant therapy efficacy in bladder cancer","volume":"22","author":"Suartz","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.01.029_b0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0105","article-title":"Split-dose cisplatin in patients with locally advanced or metastatic urothelial carcinoma: a systematic literature review and network meta-analysis","volume":"22","author":"O\u2019Dwyer","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.01.029_b0110","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/j.clgc.2018.02.002","article-title":"Feasibility of cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with diminished renal function","volume":"16","author":"Koshkin","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.01.029_b0115","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.029_b0120","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdz296","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees","volume":"30","author":"Horwich","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2025.07.002","article-title":"Neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in nonurothelial histologic subtypes of muscle-invasive bladder cancer: a phase 2 trial","volume":"88","author":"Raychaudhuri","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.juro.2013.09.009","article-title":"Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns","volume":"191","author":"Patel","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512053","article-title":"Complete transurethral resection before radical cystectomy may improve oncological outcomes","volume":"106","author":"Graffeille","year":"2022","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2026.01.029_b0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2023.06.014","article-title":"Long-term outcomes from a phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695)","volume":"84","author":"Flaig","year":"2023","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2026.01.029_b0150","doi-asserted-by":"crossref","first-page":"S1648","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.029_b0175","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.029_b0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0185","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2026.01.029_b0190","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.029_b0195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.029_b0200","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.029_b0205","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0210","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.029_b0215","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2026.01.029_b0220","unstructured":"Natera. IMVIGOR011 bladder cancer trial achieves positive results, with SIGNATERA strongly predicting adjuvant immunotherapy benefit. Press release, August 18, 2025. https:\/\/www.natera.com\/company\/news\/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit."},{"key":"10.1016\/j.eururo.2026.01.029_b0225","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5489\/cuaj.4126","article-title":"Pathology review impacts clinical management of patients with T1-T2 bladder cancer","volume":"11","author":"Traboulsi","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2026.01.029_b0230","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/BLC-190239","article-title":"Bladder cancer multidisciplinary clinic (BCMC) model influences disease assessment and impacts treatment recommendations","volume":"5","author":"Diamantopoulos","year":"2019","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2026.01.029_b0235","first-page":"199","article-title":"Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer","volume":"10","author":"Singh","year":"2024","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2026.01.029_b0240","article-title":"Disease management of clinical complete responders to neoadjuvant chemotherapy of muscle-invasive bladder cancer: a review of literature","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0245","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1200\/JCO-25-01608","article-title":"End points for the next-generation bladder-sparing perioperative trials for patients with muscle-invasive bladder cancer","volume":"43","author":"Necchi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0250","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1200\/JCO.2000.18.18.3295","article-title":"How are you feeling? Who wants to know? Patients\u2019 and oncologists\u2019 preferences for discussing health-related quality-of-life issues","volume":"18","author":"Detmar","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0363","article-title":"Patient experience captured by quality-of-life measurement in oncology clinical trials","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2026.01.029_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102369","article-title":"Association between rheumatoid arthritis, frailty status, and mortality in older adults with bladder cancer","volume":"23","author":"Swaminathan","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.01.029_b0265","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.urolonc.2020.04.036","article-title":"Assessments of frailty in bladder cancer","volume":"38","author":"Grimberg","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0270","doi-asserted-by":"crossref","first-page":"468.e7","DOI":"10.1016\/j.urolonc.2025.03.025","article-title":"Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping","volume":"43","author":"Cavanaugh","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.01.029_b0275","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.euf.2019.05.016","article-title":"Multimodal prehabilitation to enhance functional capacity following radical cystectomy: a randomized controlled trial","volume":"7","author":"Minnella","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.01.029_b0280","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2020.06.039","article-title":"Reporting radical cystectomy outcomes following implementation of enhanced recovery after surgery protocols: a systematic review and individual patient data meta-analysis","volume":"78","author":"Williams","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0285","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1007\/s00345-020-03133-y","article-title":"Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols","volume":"38","author":"Wessels","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.01.029_b0290","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jamasurg.2022.7652","article-title":"Implementation and assessment of no opioid prescription strategy at discharge after major urologic cancer surgery","volume":"158","author":"Mian","year":"2023","journal-title":"JAMA Surg"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382600059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382600059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:34:07Z","timestamp":1779917647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382600059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S030228382600059X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.029","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}